Prosensa advances DMD candidates for GSK
This article was originally published in Scrip
Executive Summary
Dutch biotech firm Prosensa could receive up to £27 million in development and milestone payments from GlaxoSmithKline for advancing three exon skipping candidates for Duchenne muscular dystrophy (DMD) into the next development stage, under an ongoing collaboration in this indication.